



(51) International Patent Classification:

A61K 31/33 (2006.01) *A61K 31/35* (2006.01)
A61K 31/335 (2006.01) *A61K 31/352* (2006.01)

(21) International Application Number:

PCT/US2023/060181

(22) International Filing Date:

05 January 2023 (05.01.2023)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/297,116 06 January 2022 (06.01.2022) US


(71) Applicant: **IMMUNEERING CORPORATION**
[US/US]; 245 Main St, 2nd Floor, Cambridge, Massachusetts 02142 (US).(72) Inventors: **HALL, Brett Matthew**; 245 Main St, 2nd Floor, Cambridge, Massachusetts 02142 (US). **DECORTE, Bart Lieven**; 245 Main St, 2nd Floor, Cambridge, Massachusetts 02142 (US). **KING, Peter John**; 245 Main St, 2nd Floor, Cambridge, Massachusetts 02142 (US). **LEEN-**

DERS, Ruben; 245 Main St, 2nd Floor, Cambridge, Massachusetts 02142 (US). **WEGERT, Anita**; 245 Main St, 2nd Floor, Cambridge, Massachusetts 02142 (US). **FOWLER, Kevin**; 245 Main St, 2nd Floor, Cambridge, Massachusetts 02142 (US). **KOLITZ, Sarah**; 245 Main St, 2nd Floor, Cambridge, Massachusetts 02142 (US). **DOODEMAN, Robin**; 245 Main St, 2nd Floor, Cambridge, Massachusetts 02142 (US). **POELAKKER, Jarno**; 245 Main St, 2nd Floor, Cambridge, Massachusetts 02142 (US). **FOLMER, Rutger Henk Adriaan**; 245 Main St, 2nd Floor, Cambridge, Massachusetts 02142 (US).

(74) Agent: **LOZAN, Vladimir Sergey**; 2040 Main Street, 14th Floor, Irvine, California 92614 (US).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS,

(54) Title: MEK IMMUNE ONCOLOGY INHIBITORS AND THERAPEUTIC USES THEREOF



Dose Response: A375 Melanoma Model




FIG. 2B

HillSlope	-0.4931
IC50	91.44

(57) **Abstract:** The present disclosure provides compounds, compositions containing such compounds, and methods of designing, developing, producing and preparing compounds represented by general Formula (III), including pharmaceutically acceptable salts thereof or a synthetic intermediate thereof. The compounds act as MEK inhibitors and are capable of displaying one or more beneficial therapeutic effects, including treating cancer.

[Continued on next page]

RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

- (84) Designated States** (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*